Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumour × Epirubicin × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 78 Triple Negative Breast Neoplasms 15 Stomach Neoplasms 12 Inflammatory Breast Neoplasms 11 Esophageal Neoplasms 6 Lymphoma, Large B-Cell, Diffuse 5 Testicular Neoplasms 3 Lymphoma 3 Urinary Bladder Neoplasms 2 Sarcoma 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasms, Germ Cell and Embryonal 2 Lymphoma, B-Cell, Marginal Zone 2 Carcinoma, Hepatocellular 2 Adenocarcinoma Of Esophagus 2 Women With Primary Breast Cancer 1 Upper Tract Urothelial Carcinoma 1 Thymoma 1 Testicular Germ Cell Tumor 1 Small Cell Lung Cancer Extensive Stage 1 Rare Tumour 1 Prostatic Neoplasms 1 Primary Breast Cancer 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Non-Muscle Invasive Bladder Neoplasms 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neoplasm Micrometastasis 1 Neoplasm Metastasis 1

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡